Table 7 Subsequent therapy after nivolumab progression
From: Low-dose nivolumab in advanced hepatocellular carcinoma
Category | (n = 78) |
|---|---|
Any post-nivolumab anti-cancer treatment | 31 (39.7%) |
Targeted therapy | |
 Lenvatinib | 7 (9.0%) |
 Sorafenib | 3 (3.8%) |
 Regorafenib | 3 (3.8%) |
 Ramucirumab | 5 (6.4%) |
 Thalidomide | 1 (1.3%) |
Chemotherapy | |
 FOLFOX | 10 (12.8%) |
 Epirubicin | 3 (3.8%) |
 Gemcitabine | 2 (2.6%) |
Immune checkpoint inhibitors | |
 Atezolizumab plus bevacizumab | 4 (5.1%) |